High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial

BACKGROUND: Acute respiratory failure (ARF) is the leading reason for intensive care unit (ICU) admission in immunocompromised patients. High-flow nasal oxygen (HFNO) therapy is an alternative to standard oxygen. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates v...

Descripción completa

Detalles Bibliográficos
Autores principales: Azoulay, Elie, Lemiale, Virginie, Mokart, Djamel, Nseir, Saad, Argaud, Laurent, Pène, Frédéric, Kontar, Loay, Bruneel, Fabrice, Klouche, Kada, Barbier, François, Reignier, Jean, Stoclin, Anabelle, Louis, Guillaume, Constantin, Jean-Michel, Mayaux, Julien, Wallet, Florent, Kouatchet, Achille, Peigne, Vincent, Perez, Pierre, Girault, Christophe, Jaber, Samir, Oziel, Johanna, Nyunga, Martine, Terzi, Nicolas, Bouadma, Lila, Lebert, Christine, Lautrette, Alexandre, Bigé, Naike, Raphalen, Jean-Herlé, Papazian, Laurent, Rabbat, Antoine, Darmon, Michael, Chevret, Sylvie, Demoule, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836389/
https://www.ncbi.nlm.nih.gov/pubmed/29506579
http://dx.doi.org/10.1186/s13063-018-2492-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836389/
https://www.ncbi.nlm.nih.gov/pubmed/29506579
http://dx.doi.org/10.1186/s13063-018-2492-z

Ejemplares similares